Novavax (NVAX) will be able to pursue emergency use authorization following new information that shows its COVID-19 vaccine is 90% effective.
The company’s authorization, which will likely be filed in the third quarter of this year, would make it the fourth to be available in the U.S. if greenlit by the U.S. Food and Drug Administration (FDA).
The Phase 3 trial in the U.S. and Mexico tested the vaccine in 30,000 individuals.It’s most differentiating factor was the presence of all coronavirus…
Source link
